TORONTO, Oct. 25 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (“Lorus”) (TSX: LOR - News; AMEX: LRP - News), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, announces the presentation of GTI-2040 pharmacokinetic and metabolic data at the 14th North American International Society for the Study of Xenobiotics (ISSX) Meeting in Puerto Rico (October 22-26, 2006).
